Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
269 hedge funds and large institutions have $1.53B invested in Catalyst Pharmaceutical in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 107 increasing their positions, 70 reducing their positions, and 40 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 70
33% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 40
6% more capital invested
Capital invested by funds: $1.45B → $1.53B (+$81.6M)
4% more funds holding
Funds holding: 259 → 269 (+10)
0.62% more ownership
Funds ownership: 81.06% → 81.68% (+0.62%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
16% less call options, than puts
Call options by funds: $1.78M | Put options by funds: $2.13M
Top Buyers
| 1 |
BlackRock
New York
|
+$28.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$25.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$23.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$20.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$32M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$9.83M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.14M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$5.04M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.81M |
CPRX Hedge Fund Activity: Q1 2024 in Review
269 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2024, worth a combined $1.53B — up 5.6% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new CPRX positions and 40 closed out — a net gain of 13 holders — while 107 added to existing stakes and 70 trimmed.
The largest buyer was BlackRock, adding an estimated $28.8M. The largest seller was Morgan Stanley, cutting an estimated $32M.
- 269 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2024, up from 259 in Q4 2023.
- Funds reported $1.53B of Catalyst Pharmaceutical stock for Q1 2024, up 5.6% quarter-over-quarter.
- 53 funds opened new Catalyst Pharmaceutical positions in Q1 2024 and 40 closed out, a net change of +13 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2024 was BlackRock, an estimated $28.8M added.
- The largest Catalyst Pharmaceutical seller in Q1 2024 was Morgan Stanley, an estimated $32M sold.
Based on aggregated 13F filings for Q1 2024.